title: Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment.
abstract: This article provides a review of the various types of antiphospholipid (aPL) antibodies and antiphospholipid syndromes, their prevalence, presumed origin, relationship to autoimmunity in general, and their role in the body's defenses and apoptosis. New hypotheses such as the role of antibodies to beta2 glycoprotein I (beta2GPI) and the signaling of toll-like receptors are also discussed, as is the spectrum of clinical manifestations associated with the demonstration of these antibodies, now assumed to be "pathogenic." A distinction is made between antibodies present in sera of patients with a variety of microangiopathic syndromes (MAPS; e.g., HELLP syndrome, thrombotic thrombocytopenic purpura, and thrombotic microangiopathic syndromes). In these conditions, the antibodies might not be "pathogenic" but, alternatively, generated by small vessel endothelial damage. These conditions are differentially referred to as microangiopathic antiphospholipid-associated syndromes, and they should be differentiated from the microvascular occlusions that are seen in the antiphospholipid syndrome. Current treatments of the antiphospholipid syndrome are briefly reviewed.
authors: Division of Immunology, The School of Pathology, University of the Witwatersrand, The Netcare Rosebank Hospital, Rosebank, Johannesburg, South Africa. ashron@icon.co.za
authors: Ronald A
authors: RA
authors: Asherson
authors: Ricard
authors: R
authors: Cervera
authors: Joan T
authors: JT
authors: Merrill
authors: Doruk
authors: D
authors: Erkan
mesh_terms: D000026:Abortion, Habitual / Q000209:etiology / Q000276:immunology; D017153:Antibodies, Anticardiolipin / Q000097:blood / Q000276:immunology; D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000276:immunology*; D000918:Antibody Specificity; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology; D001847:Bone Diseases / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000276:immunology; D005260:Female; D005317:Fetal Growth Retardation / Q000209:etiology; D005767:Gastrointestinal Diseases / Q000209:etiology; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology; D016682:Lupus Coagulation Inhibitor / Q000097:blood / Q000276:immunology; D009422:Nervous System Diseases / Q000209:etiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000209:etiology; D011516:Prothrombin / Q000276:immunology; D012871:Skin Diseases / Q000209:etiology; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D053482:beta 2-Glycoprotein I / Q000032:analysis / Q000276:immunology
chemical_list: D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D001324:Autoantigens; D016682:Lupus Coagulation Inhibitor; D053482:beta 2-Glycoprotein I; D011516:Prothrombin